Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide

Weiwen Deng, Rose Claire St. Hilaire, Natasha Chattergoon, James R. Jeter, Philip J. Kadowitz

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Calcitonin gene-related peptide (CGRP) has a beneficial effect in pulmonary hypertension and is a target for cardiovascular gene therapy. Marrow stromal cells (MSCs), also known as mesenchymal stem cells, hold promise for use in adult stem cell-based ex vivo gene therapy. To test the hypothesis that genetically engineered MSCs secreting CGRP can inhibit vascular smooth muscle cell proliferation, rat MSCs were isolated, ex vivo expanded, and transduced with adenovirus containing CGRP. Immunocytochemical analysis demonstrated that wild type rat MSCs express markers specific for stem cells, endothelial cells, and smooth muscle cells including Thy-1, c-Kit, von Willebrand Factor and α-smooth muscle actin. Immunocytochemistry confirmed the expression of CGRP by the transduced rat MSCs. The transduced rat MSCs released 10.3 ± 1.3 pmol CGRP/1 × 106 cells/48 h (mean ± S.E.M., n = 3) into culture medium at MOI 300 and the CGRP-containing culture supernatant from the transduced cells inhibited the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) and rat aortic smooth muscle cells (ASMCs) in culture. Co-culture of the transduced rat MSCs with rat PASMCs or rat ASMCs also inhibited smooth muscle cell proliferation. These findings suggest that this novel adult stem cell-based CGRP gene therapy has potential for the treatment of cardiovascular diseases including pulmonary hypertension.

    Original languageEnglish (US)
    Pages (from-to)1830-1838
    Number of pages9
    JournalLife Sciences
    Volume78
    Issue number16
    DOIs
    StatePublished - Mar 13 2006

    Fingerprint

    Calcitonin Gene-Related Peptide
    Cell proliferation
    Stromal Cells
    Vascular Smooth Muscle
    Smooth Muscle Myocytes
    Muscle
    Rats
    Bone Marrow
    Cell Proliferation
    Stem cells
    Gene therapy
    Genetic Therapy
    Adult Stem Cells
    Cells
    Cell culture
    Pulmonary Hypertension
    Pulmonary Artery
    In Vitro Techniques
    Pulmonary diseases
    Endothelial cells

    Keywords

    • Adenovirus
    • Calcitonin gene-related peptide
    • Cardiovascular diseases
    • Cell proliferation
    • Gene therapy
    • Marrow stromal cells
    • Mesenchymal stem cells
    • Pulmonary hypertension
    • Vascular smooth muscle cells

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide. / Deng, Weiwen; St. Hilaire, Rose Claire; Chattergoon, Natasha; Jeter, James R.; Kadowitz, Philip J.

    In: Life Sciences, Vol. 78, No. 16, 13.03.2006, p. 1830-1838.

    Research output: Contribution to journalArticle

    Deng, Weiwen ; St. Hilaire, Rose Claire ; Chattergoon, Natasha ; Jeter, James R. ; Kadowitz, Philip J. / Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide. In: Life Sciences. 2006 ; Vol. 78, No. 16. pp. 1830-1838.
    @article{dc22987346974ccdaf2ffeaf9a4cf766,
    title = "Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide",
    abstract = "Calcitonin gene-related peptide (CGRP) has a beneficial effect in pulmonary hypertension and is a target for cardiovascular gene therapy. Marrow stromal cells (MSCs), also known as mesenchymal stem cells, hold promise for use in adult stem cell-based ex vivo gene therapy. To test the hypothesis that genetically engineered MSCs secreting CGRP can inhibit vascular smooth muscle cell proliferation, rat MSCs were isolated, ex vivo expanded, and transduced with adenovirus containing CGRP. Immunocytochemical analysis demonstrated that wild type rat MSCs express markers specific for stem cells, endothelial cells, and smooth muscle cells including Thy-1, c-Kit, von Willebrand Factor and α-smooth muscle actin. Immunocytochemistry confirmed the expression of CGRP by the transduced rat MSCs. The transduced rat MSCs released 10.3 ± 1.3 pmol CGRP/1 × 106 cells/48 h (mean ± S.E.M., n = 3) into culture medium at MOI 300 and the CGRP-containing culture supernatant from the transduced cells inhibited the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) and rat aortic smooth muscle cells (ASMCs) in culture. Co-culture of the transduced rat MSCs with rat PASMCs or rat ASMCs also inhibited smooth muscle cell proliferation. These findings suggest that this novel adult stem cell-based CGRP gene therapy has potential for the treatment of cardiovascular diseases including pulmonary hypertension.",
    keywords = "Adenovirus, Calcitonin gene-related peptide, Cardiovascular diseases, Cell proliferation, Gene therapy, Marrow stromal cells, Mesenchymal stem cells, Pulmonary hypertension, Vascular smooth muscle cells",
    author = "Weiwen Deng and {St. Hilaire}, {Rose Claire} and Natasha Chattergoon and Jeter, {James R.} and Kadowitz, {Philip J.}",
    year = "2006",
    month = "3",
    day = "13",
    doi = "10.1016/j.lfs.2005.08.042",
    language = "English (US)",
    volume = "78",
    pages = "1830--1838",
    journal = "Life Sciences",
    issn = "0024-3205",
    publisher = "Elsevier Inc.",
    number = "16",

    }

    TY - JOUR

    T1 - Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide

    AU - Deng, Weiwen

    AU - St. Hilaire, Rose Claire

    AU - Chattergoon, Natasha

    AU - Jeter, James R.

    AU - Kadowitz, Philip J.

    PY - 2006/3/13

    Y1 - 2006/3/13

    N2 - Calcitonin gene-related peptide (CGRP) has a beneficial effect in pulmonary hypertension and is a target for cardiovascular gene therapy. Marrow stromal cells (MSCs), also known as mesenchymal stem cells, hold promise for use in adult stem cell-based ex vivo gene therapy. To test the hypothesis that genetically engineered MSCs secreting CGRP can inhibit vascular smooth muscle cell proliferation, rat MSCs were isolated, ex vivo expanded, and transduced with adenovirus containing CGRP. Immunocytochemical analysis demonstrated that wild type rat MSCs express markers specific for stem cells, endothelial cells, and smooth muscle cells including Thy-1, c-Kit, von Willebrand Factor and α-smooth muscle actin. Immunocytochemistry confirmed the expression of CGRP by the transduced rat MSCs. The transduced rat MSCs released 10.3 ± 1.3 pmol CGRP/1 × 106 cells/48 h (mean ± S.E.M., n = 3) into culture medium at MOI 300 and the CGRP-containing culture supernatant from the transduced cells inhibited the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) and rat aortic smooth muscle cells (ASMCs) in culture. Co-culture of the transduced rat MSCs with rat PASMCs or rat ASMCs also inhibited smooth muscle cell proliferation. These findings suggest that this novel adult stem cell-based CGRP gene therapy has potential for the treatment of cardiovascular diseases including pulmonary hypertension.

    AB - Calcitonin gene-related peptide (CGRP) has a beneficial effect in pulmonary hypertension and is a target for cardiovascular gene therapy. Marrow stromal cells (MSCs), also known as mesenchymal stem cells, hold promise for use in adult stem cell-based ex vivo gene therapy. To test the hypothesis that genetically engineered MSCs secreting CGRP can inhibit vascular smooth muscle cell proliferation, rat MSCs were isolated, ex vivo expanded, and transduced with adenovirus containing CGRP. Immunocytochemical analysis demonstrated that wild type rat MSCs express markers specific for stem cells, endothelial cells, and smooth muscle cells including Thy-1, c-Kit, von Willebrand Factor and α-smooth muscle actin. Immunocytochemistry confirmed the expression of CGRP by the transduced rat MSCs. The transduced rat MSCs released 10.3 ± 1.3 pmol CGRP/1 × 106 cells/48 h (mean ± S.E.M., n = 3) into culture medium at MOI 300 and the CGRP-containing culture supernatant from the transduced cells inhibited the proliferation of rat pulmonary artery smooth muscle cells (PASMCs) and rat aortic smooth muscle cells (ASMCs) in culture. Co-culture of the transduced rat MSCs with rat PASMCs or rat ASMCs also inhibited smooth muscle cell proliferation. These findings suggest that this novel adult stem cell-based CGRP gene therapy has potential for the treatment of cardiovascular diseases including pulmonary hypertension.

    KW - Adenovirus

    KW - Calcitonin gene-related peptide

    KW - Cardiovascular diseases

    KW - Cell proliferation

    KW - Gene therapy

    KW - Marrow stromal cells

    KW - Mesenchymal stem cells

    KW - Pulmonary hypertension

    KW - Vascular smooth muscle cells

    UR - http://www.scopus.com/inward/record.url?scp=33644523417&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33644523417&partnerID=8YFLogxK

    U2 - 10.1016/j.lfs.2005.08.042

    DO - 10.1016/j.lfs.2005.08.042

    M3 - Article

    C2 - 16325211

    AN - SCOPUS:33644523417

    VL - 78

    SP - 1830

    EP - 1838

    JO - Life Sciences

    JF - Life Sciences

    SN - 0024-3205

    IS - 16

    ER -